Insight Molecular Diagnostics Inc. (IMDX) stock
IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
$1.78−0.08 (-4.30%)
Close on Nov 17, 2026Market cap $58.25MP/E –Yield –
Insight Molecular Diagnostics total assets
Total assets on the balance sheet at the end of each period.
Insight Molecular Diagnostics's total assets was $29.44M at Jun 30, 2026. For fiscal 2025 it was $25.76M, down 26.6% from the year before. Over ten years it grew 7.3% a year on average. The highest annual figure on record is $159.56M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.76M | -26.6% |
| FY2024 | Dec 31, 2024 | $35.08M | -53.2% |
| FY2023 | Dec 31, 2023 | $74.89M | -25.2% |
| FY2022 | Dec 31, 2022 | $100.09M | -37.3% |
| FY2021 | Dec 31, 2021 | $159.56M | +187.9% |
| FY2020 | Dec 31, 2020 | $55.42M | +39.0% |
| FY2019 | Dec 31, 2019 | $39.86M | +318.8% |
| FY2018 | Dec 31, 2018 | $9.52M | -6.8% |
| FY2017 | Dec 31, 2017 | $10.22M | -29.3% |
| FY2016 | Dec 31, 2016 | $14.45M | +13.5% |
| FY2015 | Dec 31, 2015 | $12.73M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $29.44M | -41.7% |
| Q1 FY2026 | Mar 31, 2026 | $40.43M | -33.0% |
| Q4 FY2025 | Dec 31, 2025 | $25.76M | -26.6% |
| Q3 FY2025 | Sep 30, 2025 | $43.94M | -37.4% |
| Q2 FY2025 | Jun 30, 2025 | $50.52M | -32.4% |
| Q1 FY2025 | Mar 31, 2025 | $60.36M | -15.0% |
| Q4 FY2024 | Dec 31, 2024 | $35.08M | -53.2% |
| Q3 FY2024 | Sep 30, 2024 | $70.22M | -13.9% |
| Q2 FY2024 | Jun 30, 2024 | $74.72M | -14.6% |
| Q1 FY2024 | Mar 31, 2024 | $70.97M | -14.3% |
| Q4 FY2023 | Dec 31, 2023 | $74.89M | -25.2% |
| Q3 FY2023 | Sep 30, 2023 | $81.59M | -48.1% |
| Q2 FY2023 | Jun 30, 2023 | $87.54M | -48.8% |
| Q1 FY2023 | Mar 31, 2023 | $82.80M | -43.4% |
| Q4 FY2022 | Dec 31, 2022 | $100.09M | -37.3% |
| Q3 FY2022 | Sep 30, 2022 | $157.34M | -6.5% |
| Q2 FY2022 | Jun 30, 2022 | $171.05M | -3.6% |
| Q1 FY2022 | Mar 31, 2022 | $146.27M | +13.1% |
| Q4 FY2021 | Dec 31, 2021 | $159.56M | +187.9% |
| Q3 FY2021 | Sep 30, 2021 | $168.34M | +191.4% |
| Q2 FY2021 | Jun 30, 2021 | $177.38M | +179.5% |
| Q1 FY2021 | Mar 31, 2021 | $129.31M | +117.3% |
| Q4 FY2020 | Dec 31, 2020 | $55.42M | +39.0% |
| Q3 FY2020 | Sep 30, 2020 | $57.78M | +76.3% |
| Q2 FY2020 | Jun 30, 2020 | $63.46M | +68.5% |
| Q1 FY2020 | Mar 31, 2020 | $59.50M | +42.8% |
| Q4 FY2019 | Dec 31, 2019 | $39.86M | +318.8% |
| Q3 FY2019 | Sep 30, 2019 | $32.77M | +153.9% |
| Q2 FY2019 | Jun 30, 2019 | $37.67M | +208.8% |
| Q1 FY2019 | Mar 31, 2019 | $41.68M | +167.5% |
| Q4 FY2018 | Dec 31, 2018 | $9.52M | -6.8% |
| Q3 FY2018 | Sep 30, 2018 | $12.91M | -9.4% |
| Q2 FY2018 | Jun 30, 2018 | $12.20M | +0.5% |
| Q1 FY2018 | Mar 31, 2018 | $15.58M | +2.7% |
| Q4 FY2017 | Dec 31, 2017 | $10.22M | -29.3% |
| Q3 FY2017 | Sep 30, 2017 | $14.25M | -15.5% |
| Q2 FY2017 | Jun 30, 2017 | $12.14M | – |
| Q1 FY2017 | Mar 31, 2017 | $15.17M | – |
| Q4 FY2016 | Dec 31, 2016 | $14.45M | – |
| Q3 FY2016 | Sep 30, 2016 | $16.86M | – |
See a number that looks wrong?